Our analysts believe a long-term margin recovery is underway.

Investors are ignoring a strong long-term outlook.

Shares plunge after guidance is cut.

Sales growth at CSL was lower than expected but streamlining the business has its perks.

Cochlear’s met expectations, but investors overly optimistic.

Margins improve but primary market is limited.

Shares soared 30% in the last week but are still undervalued.

Despite our lower fair value the shares are still attractive.

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.

Trump’s announcement could directly affect CSL, but we expect the firm to respond accordingly.